March 21, 2025

Vutrisiran Receives FDA Nod for ATTR Amyloidosis With Cardiomyopathy

The FDA approves vutrisiran (Amvuttra) as the first RNAi therapeutic to reduce cardiovascular events and mortality in adults with transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.

Conexiant

March 21, 2025

FDA Approves Guselkumab for Crohn’s Disease

The FDA has approved guselkumab (TREMFYA®) for moderately to severely active Crohn’s disease, supported by Phase 3 trial data showing clinical and endoscopic superiority over ustekinumab.

Conexiant

March 21, 2025

Peripheral Biomarker Signatures May Improve RA-ILD Detection

Distinct peripheral biomarker signatures improved RA-ILD identification beyond clinical risk factors, with an AUC of 0.751.

Conexiant

March 19, 2025

Awake Prone Positioning May Reduce COVID-19 Intubation

Researchers found that awake prone positioning was associated with improved survival without intubation and reduced mortality in patients with COVID-19 and acute hypoxemic respiratory failure.

Conexiant

March 19, 2025

Study: Sex Differences in Physician Suicide

Researchers found that female physicians had a significantly higher suicide risk than female nonphysicians.

Conexiant

March 14, 2025

FDA Recommends Influenza Vaccine Strains for 2025 to 2026

The FDA has selected influenza vaccine strains for the 2025 to 2026 U.S. flu season, maintaining consistency with prior formulations while incorporating updated epidemiologic and antigenic data to optimize protection.

Conexiant

March 13, 2025

FDA Chief Counsel Resigns Two Days In

U.S. FDA's chief counsel resigns amidst controversy surrounding her appointment and connections to mifepristone during the Biden administration.

Reuters

March 12, 2025

MRI Shows Persistent Gut Dysfunction in Celiac Despite Gluten-Free Diet

MRI findings show persistent gut motility and microbiome alterations in celiac disease despite a gluten-free diet.

Conexiant

March 12, 2025

Blood Donation Reshapes Stem Cell Mutations

Researchers discover erythropoietin released after blood donation selectively favors specific DNMT3A mutations in stem cells, revealing how frequent donation creates evolutionary pressure that differs from cancer-associated pathways.

Conexiant